TD Cowen Reiterates Buy Rating on Exelixis (EXEL)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
October 16, 2024 6:54 AM EDTLeerink Partners analyst Christopher Liu reiterated a Market Perform rating and $28.50 price target on Exelixis (NASDAQ: EXEL)
The analyst comments "Bottom Line: The long-awaited decision (here) in the patent infringement trial vs MSN (private) on Cabometyx was issued on October 15 intraday, which is a positive development for EXEL. For the malate salt patents comprising '439, '440 and '015 expiring Jan 2030, the Judge found the patents valid. Additionally, the Judge found that Claim 3 of the '349 patent (referring to formulation impurities for cabo, potentially during the manufacturing/synthesis... More
Exelixis (EXEL) PT Raised to $34 at RBC Capital
October 16, 2024 6:50 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Exelixis (NASDAQ: EXEL) to $34.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Today's ruling in favor of Cabo's protection into 2030 has, in our view, created a refreshed forward-orienting set-up for shares with... More
Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
October 16, 2024 6:03 AM EDTGoldman Sachs analyst Chris Shibutani reiterated a Sell rating and $18.00 price target on Exelixis (NASDAQ: EXEL).
The analyst comments "The US District Court in Delaware ruled in favor of Exelixis in the "MSN II" case rejecting the challenge posed by MSN to three Orange Book-listed patents relating to EXEL's cabozantinib, assuring protection from generic entry... More
